Clinical responses to anticancer therapies in advanced soft tissue sarcoma (STS) are unfortunately limited to a small subset of patients. Much of the inter-individual variability in treatment efficacy and risk of toxicities is as result of polymorphisms in genes encoding proteins involved in drug pharmacokinetics and pharmacodynamics. Therefore, the detection of pharmacogenomics (PGx) biomarkers that might predict drug response and toxicity can be useful to explain the genetic basis for the differences in treatment efficacy and toxicity among STS pa- tients. PGx markers are frequently located in transporters, drug-metabolizing enzyme genes, drug targets, or HLA alleles. Along this line, genetic variability harbouring in the germline genome of the patients can influence systemic pharmacokinetics and pharmacodynamics of the treatments, acting as predictive biomarkers for drug- induced toxicity and treatment efficacy. By linking drug activity to the functional complexity of cancer genomes, also systematic pharmacogenomic profiling in cancer cell lines and primary STS samples represents area of active investigation that could eventually lead to enhanced efficacy and offer a powerful biomarker discovery platform to optimize current treatments and improve the knowledge about the individual’s drug response in STS patients into the clinical practice

Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity / Gambale, Elisabetta; Boddi, Anna; Pasqui, Adriano; Campanacci, Domenico Andrea; Scoccianti, Guido; Palchetti, Ilaria; Bernini, Andrea; Antonuzzo, Lorenzo; Pillozzi, Serena. - In: CANCER TREATMENT AND RESEARCH COMMUNICATIONS. - ISSN 2468-2942. - STAMPA. - 31:(2022), pp. 0-0. [10.1016/j.ctarc.2022.100528]

Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity

Gambale, Elisabetta;Campanacci, Domenico Andrea;Scoccianti, Guido;Palchetti, Ilaria;Antonuzzo, Lorenzo;Pillozzi, Serena
2022

Abstract

Clinical responses to anticancer therapies in advanced soft tissue sarcoma (STS) are unfortunately limited to a small subset of patients. Much of the inter-individual variability in treatment efficacy and risk of toxicities is as result of polymorphisms in genes encoding proteins involved in drug pharmacokinetics and pharmacodynamics. Therefore, the detection of pharmacogenomics (PGx) biomarkers that might predict drug response and toxicity can be useful to explain the genetic basis for the differences in treatment efficacy and toxicity among STS pa- tients. PGx markers are frequently located in transporters, drug-metabolizing enzyme genes, drug targets, or HLA alleles. Along this line, genetic variability harbouring in the germline genome of the patients can influence systemic pharmacokinetics and pharmacodynamics of the treatments, acting as predictive biomarkers for drug- induced toxicity and treatment efficacy. By linking drug activity to the functional complexity of cancer genomes, also systematic pharmacogenomic profiling in cancer cell lines and primary STS samples represents area of active investigation that could eventually lead to enhanced efficacy and offer a powerful biomarker discovery platform to optimize current treatments and improve the knowledge about the individual’s drug response in STS patients into the clinical practice
2022
31
0
0
Gambale, Elisabetta; Boddi, Anna; Pasqui, Adriano; Campanacci, Domenico Andrea; Scoccianti, Guido; Palchetti, Ilaria; Bernini, Andrea; Antonuzzo, Lore...espandi
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S2468294222000193-main.pdf

accesso aperto

Licenza: Creative commons
Dimensione 2.85 MB
Formato Adobe PDF
2.85 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1256632
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact